semaglutide with cagrilintide CagriSema (Cagrilintide–Semaglutide) in Adults Overweight or Obesity and Type 2 Diabetes In the REDEFINE 1 phase

Under the deal, Novo Nordisk has secured the exclusive worldwide license to use Ascendis TransCon technology platform to develop, produce, and sell products for metabolic diseases, including obesity and Type 2 diabetes with the primary goal being to develop a monthly GLP-1

The Missing Link in Body Contouring Why Results Stall Without L-Carnitine

We are committed to providing ongoing support and careful medical oversight throughout your Ozempic treatment journey

Making strides to improve glutathione levels is key to altering the premature aging that is often seen in patients with DS

Endogenous GIP is secreted most potently in response to high lipid meals [16], while GIP infusion enhances adipose tissue blood flow in lean patients [17] and lipid deposition (e.g., reduced plasma non-essential fatty acids (NEFA), increased adipose triglycerides (TG)) in patients with obesity and type 2 diabetes (T2D) [18]